{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:06:34Z","timestamp":1781625994212,"version":"3.54.5"},"reference-count":107,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"NIH","award":["RO1 HD094378"],"award-info":[{"award-number":["RO1 HD094378"]}]},{"name":"NIH","award":["RO1 ES028615"],"award-info":[{"award-number":["RO1 ES028615"]}]},{"name":"NIH","award":["U54 MD007602 RO1 HD094378"],"award-info":[{"award-number":["U54 MD007602 RO1 HD094378"]}]},{"name":"NIH","award":["U54 MD007602"],"award-info":[{"award-number":["U54 MD007602"]}]},{"DOI":"10.13039\/100032802","name":"SEUD","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100032802","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Reprod. Sci."],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Uterine fibroids (UFs), the most common gynecologic tumors in reproductive-age women, are characterized by the accumulation of extracellular matrix (ECM), which leads to increased stiffness. The stiffness can transfer mechanical signals from the ECM to the intracellular environment through a process called mechanotransduction, consequently altering the biological behavior of the cell. UFs are estrogen and progesterone-dependent, with hormonal fluctuations influencing their growth and development. Consequently, the emphasis in medical treatment development has been on options that target steroid hormones, including GnRH agonists\/antagonists, aromatase inhibitors, and anti-progestins. However, there has been limited understanding of how mechanical stiffness influences the progression of UFs and their cells\u2019 response to medical treatments. This work aimed to assess the impact of stiffness on UFs cell growth and on their responsiveness to hormone and anti-hormonal treatments. Our results showed that increased stiffness enhances proliferation and ECM accumulation in UF cells, and that the mechanical environment influences the response of these cells to both hormone and anti-hormone treatments. These findings offer valuable insights for understanding UF pathogenesis, racial disparity as well as improving UF treatment strategies, emphasizing the importance of considering the mechanical microenvironment in clinical approaches.<\/jats:p>","DOI":"10.1007\/s43032-025-02016-0","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T16:00:05Z","timestamp":1765209605000},"page":"129-140","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mechanical Stiffness Influences the Response of Human Uterine Fibroid Cells to Hormonal Treatments"],"prefix":"10.1007","volume":"33","author":[{"given":"Maria Victoria","family":"Bariani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emnet","family":"Djibrila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise","family":"Maajid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiwei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8778-4447","authenticated-orcid":false,"given":"Ayman","family":"Al-Hendy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9675-6691","authenticated-orcid":false,"given":"Mohamed","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,8]]},"reference":[{"issue":"9252","key":"2016_CR1","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S0140-6736(00)03622-9","volume":"357","author":"EA Stewart","year":"2001","unstructured":"Stewart EA. Uterine fibroids. Lancet. 2001;357(9252):293\u20138.","journal-title":"Lancet"},{"issue":"4","key":"2016_CR2","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1210\/endrev\/bnab039","volume":"43","author":"Q Yang","year":"2022","unstructured":"Yang Q, et al. Comprehensive review of uterine fibroids: developmental origin, pathogenesis, and treatment. Endocr Rev. 2022;43(4):678\u2013719.","journal-title":"Endocr Rev"},{"key":"2016_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jeud.2023.100018","author":"M Ali","year":"2023","unstructured":"Ali M, et al. Prevention of uterine fibroids: molecular mechanisms and potential clinical application. J Endometr Uterine Disord. 2023. https:\/\/doi.org\/10.1016\/j.jeud.2023.100018.","journal-title":"J Endometr Uterine Disord"},{"issue":"6","key":"2016_CR4","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1097\/MED.0000000000000578","volume":"27","author":"MV Bariani","year":"2020","unstructured":"Bariani MV, et al. The role of endocrine-disrupting chemicals in uterine fibroid pathogenesis. Curr Opin Endocrinol Diabetes Obes. 2020;27(6):380\u20137.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"4","key":"2016_CR5","doi-asserted-by":"publisher","first-page":"368504231215601","DOI":"10.1177\/00368504231215601","volume":"106","author":"Q Yang","year":"2023","unstructured":"Yang Q, et al. Endocrine-disrupting chemicals and epigenetic reprogramming in developmental origin of uterine fibroids. Sci Prog. 2023;106(4):368504231215601.","journal-title":"Sci Prog"},{"issue":"3","key":"2016_CR6","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.ajog.2013.08.008","volume":"210","author":"HM Eltoukhi","year":"2014","unstructured":"Eltoukhi HM, et al. The health disparities of uterine fibroid tumors for African American women: a public health issue. Am J Obstet Gynecol. 2014;210(3):194\u20139.","journal-title":"Am J Obstet Gynecol"},{"issue":"11","key":"2016_CR7","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1089\/jwh.2018.7076","volume":"27","author":"EE Marsh","year":"2018","unstructured":"Marsh EE, et al. Burden, prevalence, and treatment of uterine fibroids: a survey of U.S. women. J Womens Health. 2018;27(11):1359\u201367.","journal-title":"J Womens Health"},{"issue":"7","key":"2016_CR8","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1016\/j.fertnstert.2013.02.017","volume":"99","author":"EE Marsh","year":"2013","unstructured":"Marsh EE, et al. Racial differences in fibroid prevalence and ultrasound findings in asymptomatic young women (18\u201330 years old): a pilot study. Fertil Steril. 2013;99(7):1951\u20137.","journal-title":"Fertil Steril"},{"key":"2016_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.43","volume":"2","author":"EA Stewart","year":"2016","unstructured":"Stewart EA, et al. Uterine fibroids. Nat Rev Dis Primers. 2016;2:16043.","journal-title":"Nat Rev Dis Primers"},{"key":"2016_CR10","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1472-6874-12-6","volume":"12","author":"A Zimmermann","year":"2012","unstructured":"Zimmermann A, et al. Prevalence, symptoms and management of uterine fibroids: an international internet-based survey of 21,746 women. BMC Womens Health. 2012;12:6.","journal-title":"BMC Womens Health"},{"issue":"1","key":"2016_CR11","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1093\/humupd\/dmx032","volume":"24","author":"MS Islam","year":"2018","unstructured":"Islam MS, et al. Extracellular matrix in uterine leiomyoma pathogenesis: a potential target for future therapeutics. Hum Reprod Update. 2018;24(1):59\u201385.","journal-title":"Hum Reprod Update"},{"key":"2016_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24065778","author":"Q Yang","year":"2023","unstructured":"Yang Q, Al-Hendy A. Update on the role and regulatory mechanism of extracellular matrix in the pathogenesis of uterine fibroids. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms24065778.","journal-title":"Int J Mol Sci"},{"issue":"Pt 24","key":"2016_CR13","doi-asserted-by":"publisher","first-page":"4195","DOI":"10.1242\/jcs.023820","volume":"123","author":"C Frantz","year":"2010","unstructured":"Frantz C, Stewart KM, Weaver VM. The extracellular matrix at a glance. J Cell Sci. 2010;123(Pt 24):4195\u2013200.","journal-title":"J Cell Sci"},{"issue":"24","key":"2016_CR14","doi-asserted-by":"publisher","first-page":"6850","DOI":"10.1111\/febs.15776","volume":"288","author":"NK Karamanos","year":"2021","unstructured":"Karamanos NK, et al. A guide to the composition and functions of the extracellular matrix. FEBS J. 2021;288(24):6850\u2013912.","journal-title":"FEBS J"},{"issue":"Suppl 3","key":"2016_CR15","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/j.fertnstert.2004.04.030","volume":"82","author":"PC Leppert","year":"2004","unstructured":"Leppert PC, et al. Comparative ultrastructure of collagen fibrils in uterine leiomyomas and normal myometrium. Fertil Steril. 2004;82(Suppl 3):1182\u20137.","journal-title":"Fertil Steril"},{"key":"2016_CR16","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/783289","volume":"2014","author":"PC Leppert","year":"2014","unstructured":"Leppert PC, Jayes FL, Segars JH. The extracellular matrix contributes to mechanotransduction in uterine fibroids. Obstet Gynecol Int. 2014;2014:783289.","journal-title":"Obstet Gynecol Int"},{"key":"2016_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.631991","volume":"11","author":"H Ge","year":"2021","unstructured":"Ge H, et al. Extracellular matrix stiffness: new areas affecting cell metabolism. Front Oncol. 2021;11:631991.","journal-title":"Front Oncol"},{"issue":"14","key":"2016_CR18","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1056\/NEJMra1209993","volume":"369","author":"SE Bulun","year":"2013","unstructured":"Bulun SE. Uterine fibroids. N Engl J Med. 2013;369(14):1344\u201355.","journal-title":"N Engl J Med"},{"issue":"5","key":"2016_CR19","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1055\/s-0035-1558451","volume":"33","author":"SE Bulun","year":"2015","unstructured":"Bulun SE, et al. Uterine leiomyoma stem cells: linking progesterone to growth. Semin Reprod Med. 2015;33(5):357\u201365.","journal-title":"Semin Reprod Med"},{"issue":"2","key":"2016_CR20","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1080\/17460441.2018.1417381","volume":"13","author":"M Ali","year":"2018","unstructured":"Ali M, Chaudhry ZT, Al-Hendy A. Successes and failures of uterine leiomyoma drug discovery. Expert Opin Drug Discov. 2018;13(2):169\u201377.","journal-title":"Expert Opin Drug Discov"},{"key":"2016_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01958-6","author":"M Ali","year":"2023","unstructured":"Ali M, et al. Current and emerging treatment options for uterine fibroids. Drugs. 2023. https:\/\/doi.org\/10.1007\/s40265-023-01958-6.","journal-title":"Drugs"},{"issue":"4","key":"2016_CR22","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1080\/14740338.2022.1989409","volume":"21","author":"M Ali","year":"2022","unstructured":"Ali M, et al. Current approaches to overcome the side effects of GnRH analogs in the treatment of patients with uterine fibroids. Expert Opin Drug Saf. 2022;21(4):477\u201386.","journal-title":"Expert Opin Drug Saf"},{"issue":"7","key":"2016_CR23","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1056\/NEJMoa2008283","volume":"384","author":"A Al-Hendy","year":"2021","unstructured":"Al-Hendy A, et al. Treatment of uterine fibroid symptoms with relugolix combination therapy. N Engl J Med. 2021;384(7):630\u201342.","journal-title":"N Engl J Med"},{"issue":"6","key":"2016_CR24","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1097\/AOG.0000000000004988","volume":"140","author":"A Al-Hendy","year":"2022","unstructured":"Al-Hendy A, et al. Long-term relugolix combination therapy for symptomatic uterine leiomyomas. Obstet Gynecol. 2022;140(6):920\u201330.","journal-title":"Obstet Gynecol"},{"issue":"4","key":"2016_CR25","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1056\/NEJMoa1904351","volume":"382","author":"WD Schlaff","year":"2020","unstructured":"Schlaff WD, et al. Elagolix for heavy menstrual bleeding in women with uterine fibroids. N Engl J Med. 2020;382(4):328\u201340.","journal-title":"N Engl J Med"},{"issue":"6","key":"2016_CR26","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1055\/s-0037-1607264","volume":"35","author":"A Al-Hendy","year":"2017","unstructured":"Al-Hendy A, Myers ER, Stewart E. Uterine fibroids: burden and unmet medical need. Semin Reprod Med. 2017;35(6):473\u201380.","journal-title":"Semin Reprod Med"},{"issue":"1","key":"2016_CR27","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.fertnstert.2020.12.011","volume":"116","author":"CN Cordeiro Mitchell","year":"2021","unstructured":"Cordeiro Mitchell CN, et al. Mechanical stiffness augments ligand-dependent progesterone receptor B activation via MEK 1\/2 and Rho\/ROCK-dependent signaling pathways in uterine fibroid cells. Fertil Steril. 2021;116(1):255\u201365.","journal-title":"Fertil Steril"},{"issue":"6","key":"2016_CR28","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1097\/01.LAB.0000017499.51216.3E","volume":"82","author":"SA Carney","year":"2002","unstructured":"Carney SA, et al. Immortalization of human uterine leiomyoma and myometrial cell lines after induction of telomerase activity: molecular and phenotypic characteristics. Lab Invest. 2002;82(6):719\u201328.","journal-title":"Lab Invest"},{"issue":"7","key":"2016_CR29","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nmeth.2089","volume":"9","author":"CA Schneider","year":"2012","unstructured":"Schneider CA, Rasband WS, Eliceiri KW. NIH image to ImageJ: 25 years of image analysis. Nat Methods. 2012;9(7):671\u20135.","journal-title":"Nat Methods"},{"issue":"1","key":"2016_CR30","doi-asserted-by":"publisher","first-page":"18784","DOI":"10.1038\/s41598-020-75738-7","volume":"10","author":"G Wu","year":"2020","unstructured":"Wu G, Gotthardt M, Gollasch M. Assessment of nanoindentation in stiffness measurement of soft biomaterials: kidney, liver, spleen and uterus. Sci Rep. 2020;10(1):18784.","journal-title":"Sci Rep"},{"issue":"2","key":"2016_CR31","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.legalmed.2013.11.005","volume":"16","author":"S Torimitsu","year":"2014","unstructured":"Torimitsu S, et al. Effects of the freezing and thawing process on biomechanical properties of the human skull. Legal Med. 2014;16(2):102\u20135.","journal-title":"Legal Med"},{"key":"2016_CR32","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.jmbbm.2017.03.006","volume":"71","author":"AE Peters","year":"2017","unstructured":"Peters AE, et al. Micromechanical properties of canine femoral articular cartilage following multiple freeze-thaw cycles. J Mech Behav Biomed Mater. 2017;71:114\u201321.","journal-title":"J Mech Behav Biomed Mater"},{"key":"2016_CR33","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1186\/1471-2474-11-231","volume":"11","author":"M Szarko","year":"2010","unstructured":"Szarko M, Muldrew K, Bertram JE. Freeze-thaw treatment effects on the dynamic mechanical properties of articular cartilage. BMC Musculoskelet Disord. 2010;11:231.","journal-title":"BMC Musculoskelet Disord"},{"issue":"7","key":"2016_CR34","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1007\/s10439-011-0506-z","volume":"40","author":"A Hemmasizadeh","year":"2012","unstructured":"Hemmasizadeh A, Darvish K, Autieri M. Characterization of changes to the mechanical properties of arteries due to cold storage using nanoindentation tests. Ann Biomed Eng. 2012;40(7):1434\u201342.","journal-title":"Ann Biomed Eng"},{"issue":"12","key":"2016_CR35","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/nrm3896","volume":"15","author":"JD Humphrey","year":"2014","unstructured":"Humphrey JD, Dufresne ER, Schwartz MA. Mechanotransduction and extracellular matrix homeostasis. Nat Rev Mol Cell Biol. 2014;15(12):802\u201312.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2016_CR36","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.gene.2019.05.003","volume":"707","author":"H Kuivaniemi","year":"2019","unstructured":"Kuivaniemi H, Tromp G. Type III collagen (COL3A1): gene and protein structure, tissue distribution, and associated diseases. Gene. 2019;707:151\u201371.","journal-title":"Gene"},{"issue":"16","key":"2016_CR37","doi-asserted-by":"publisher","first-page":"4246","DOI":"10.1111\/j.1742-4658.2007.05951.x","volume":"274","author":"C Ruhland","year":"2007","unstructured":"Ruhland C, et al. The glycosaminoglycan chain of decorin plays an important role in collagen fibril formation at the early stages of fibrillogenesis. FEBS J. 2007;274(16):4246\u201355.","journal-title":"FEBS J"},{"issue":"11","key":"2016_CR38","first-page":"740","volume":"51","author":"F Sotoodehnejadnematalahi","year":"2013","unstructured":"Sotoodehnejadnematalahi F, Burke B. Structure, function and regulation of versican: the most abundant type of proteoglycan in the extracellular matrix. Acta Med Iran. 2013;51(11):740\u201350.","journal-title":"Acta Med Iran"},{"issue":"1","key":"2016_CR39","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3390\/cancers5010027","volume":"5","author":"F Schaffner","year":"2013","unstructured":"Schaffner F, Ray AM, Dontenwill M. Integrin alpha5beta1, the fibronectin receptor, as a pertinent therapeutic target in solid tumors. Cancers (Basel). 2013;5(1):27\u201347.","journal-title":"Cancers (Basel)"},{"key":"2016_CR40","doi-asserted-by":"publisher","first-page":"13329","DOI":"10.2147\/OTT.S273803","volume":"13","author":"J Hou","year":"2020","unstructured":"Hou J, et al. The roles of integrin alpha5beta1 in human cancer. Onco Targets Ther. 2020;13:13329\u201344.","journal-title":"Onco Targets Ther"},{"issue":"9","key":"2016_CR41","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1177\/1933719116678686","volume":"24","author":"MA Borahay","year":"2017","unstructured":"Borahay MA, et al. Estrogen receptors and signaling in fibroids: role in pathobiology and therapeutic implications. Reprod Sci. 2017;24(9):1235\u201344.","journal-title":"Reprod Sci"},{"issue":"3","key":"2016_CR42","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1210\/jc.2018-01216","volume":"104","author":"SSM Ng","year":"2019","unstructured":"Ng SSM, et al. A-kinase anchoring protein 13 (AKAP13) augments progesterone signaling in uterine fibroid cells. J Clin Endocrinol Metab. 2019;104(3):970\u201380.","journal-title":"J Clin Endocrinol Metab"},{"key":"2016_CR43","doi-asserted-by":"publisher","DOI":"10.1210\/endrev\/bnab039","author":"Q Yang","year":"2021","unstructured":"Yang Q, et al. Comprehensive review of uterine fibroids: developmental origin, pathogenesis, and treatment. Endocr Rev. 2021. https:\/\/doi.org\/10.1210\/endrev\/bnab039.","journal-title":"Endocr Rev"},{"issue":"6","key":"2016_CR44","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/S0029-7844(97)00534-6","volume":"90","author":"LM Marshall","year":"1997","unstructured":"Marshall LM, et al. Variation in the incidence of uterine leiomyoma among premenopausal women by age and race. Obstet Gynecol. 1997;90(6):967\u201373.","journal-title":"Obstet Gynecol"},{"issue":"3","key":"2016_CR45","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/uog.8826","volume":"37","author":"A De Vivo","year":"2011","unstructured":"De Vivo A, et al. Uterine myomas during pregnancy: a longitudinal sonographic study. Ultrasound Obstet Gynecol. 2011;37(3):361\u20135.","journal-title":"Ultrasound Obstet Gynecol"},{"issue":"4","key":"2016_CR46","doi-asserted-by":"publisher","first-page":"319 e1","DOI":"10.1016\/j.ajog.2013.07.017","volume":"209","author":"BJ Borah","year":"2013","unstructured":"Borah BJ, et al. The impact of uterine leiomyomas: a national survey of affected women. Am J Obstet Gynecol. 2013;209(4):319 e1-319 e20.","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"2016_CR47","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1185\/03007995.2015.1107534","volume":"32","author":"PY Laberge","year":"2016","unstructured":"Laberge PY, et al. Burden of symptomatic uterine fibroids in Canadian women: a cohort study. Curr Med Res Opin. 2016;32(1):165\u201375.","journal-title":"Curr Med Res Opin"},{"issue":"10","key":"2016_CR48","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1097\/JOM.0000000000001105","volume":"59","author":"AM Soliman","year":"2017","unstructured":"Soliman AM, et al. Examining the relationship between symptomatic burden and self-reported productivity losses among patients with uterine fibroids in the United States. J Occup Environ Med. 2017;59(10):974\u201381.","journal-title":"J Occup Environ Med"},{"issue":"4","key":"2016_CR49","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.bpobgyn.2008.04.002","volume":"22","author":"S Okolo","year":"2008","unstructured":"Okolo S. Incidence, aetiology and epidemiology of uterine fibroids. Best Pract Res Clin Obstet Gynaecol. 2008;22(4):571\u201388.","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"issue":"17","key":"2016_CR50","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1056\/NEJMcp1411029","volume":"372","author":"EA Stewart","year":"2015","unstructured":"Stewart EA. Clinical practice. Uterine fibroids. N Engl J Med. 2015;372(17):1646\u201355.","journal-title":"N Engl J Med"},{"issue":"1","key":"2016_CR51","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.fertnstert.2010.08.049","volume":"95","author":"WH Catherino","year":"2011","unstructured":"Catherino WH, Parrott E, Segars J. Proceedings from thenational institute of child health and human development conference on the uterine fibroid research update workshop. Fertil Steril. 2011;95(1):9\u201312.","journal-title":"Fertil Steril"},{"issue":"3","key":"2016_CR52","doi-asserted-by":"publisher","first-page":"211.e1-9","DOI":"10.1016\/j.ajog.2011.12.002","volume":"206","author":"ER Cardozo","year":"2012","unstructured":"Cardozo ER, et al. The estimated annual cost of uterine leiomyomata in the United States. Am J Obstet Gynecol. 2012;206(3):211.e1-9.","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"2016_CR53","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.fertnstert.2015.04.021","volume":"104","author":"A Mas","year":"2015","unstructured":"Mas A, et al. Stro-1\/CD44 as putative human myometrial and fibroid stem cell markers. Fertil Steril. 2015;104(1):225\u201334.e3.","journal-title":"Fertil Steril"},{"issue":"47","key":"2016_CR54","doi-asserted-by":"publisher","first-page":"18700","DOI":"10.1073\/pnas.0704472104","volume":"104","author":"M Ono","year":"2007","unstructured":"Ono M, et al. Side population in human uterine myometrium displays phenotypic and functional characteristics of myometrial stem cells. Proc Natl Acad Sci U S A. 2007;104(47):18700\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2016_CR55","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.fertnstert.2013.03.007","volume":"100","author":"MS Islam","year":"2013","unstructured":"Islam MS, et al. Complex networks of multiple factors in the pathogenesis of uterine leiomyoma. Fertil Steril. 2013;100(1):178\u201393.","journal-title":"Fertil Steril"},{"issue":"3","key":"2016_CR56","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1055\/s-0030-1251476","volume":"28","author":"N Chegini","year":"2010","unstructured":"Chegini N. Proinflammatory and profibrotic mediators: principal effectors of leiomyoma development as a fibrotic disorder. Semin Reprod Med. 2010;28(3):180\u2013203.","journal-title":"Semin Reprod Med"},{"issue":"42","key":"2016_CR57","doi-asserted-by":"publisher","first-page":"17053","DOI":"10.1073\/pnas.1313650110","volume":"110","author":"M Ono","year":"2013","unstructured":"Ono M, et al. Paracrine activation of WNT\/beta-catenin pathway in uterine leiomyoma stem cells promotes tumor growth. Proc Natl Acad Sci USA. 2013;110(42):17053\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"2016_CR58","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0036935","volume":"7","author":"M Ono","year":"2012","unstructured":"Ono M, et al. Role of stem cells in human uterine leiomyoma growth. PLoS One. 2012;7(5):e36935.","journal-title":"PLoS One"},{"issue":"4","key":"2016_CR59","doi-asserted-by":"publisher","first-page":"E601","DOI":"10.1210\/jc.2014-2134","volume":"100","author":"P Yin","year":"2015","unstructured":"Yin P et al. Human uterine leiomyoma stem\/progenitor cells expressing CD34 and CD49b initiate tumors in vivo. J Clin Endocrinol Metab. 2015;100(4):E601\u20136.","journal-title":"J Clin Endocrinol Metab"},{"key":"2016_CR60","doi-asserted-by":"publisher","first-page":"824","DOI":"10.3389\/fphys.2018.00824","volume":"9","author":"F Martino","year":"2018","unstructured":"Martino F, et al. Cellular mechanotransduction: from tension to function. Front Physiol. 2018;9:824.","journal-title":"Front Physiol"},{"key":"2016_CR61","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a005058","author":"P Lu","year":"2011","unstructured":"Lu P, et al. Extracellular matrix degradation and remodeling in development and disease. Cold Spring Harb Perspect Biol. 2011. https:\/\/doi.org\/10.1101\/cshperspect.a005058.","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"3","key":"2016_CR62","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1172\/JCI31487","volume":"117","author":"TA Wynn","year":"2007","unstructured":"Wynn TA. Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J Clin Invest. 2007;117(3):524\u20139.","journal-title":"J Clin Invest"},{"issue":"6","key":"2016_CR63","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1055\/s-0037-1607268","volume":"35","author":"S Rafique","year":"2017","unstructured":"Rafique S, Segars JH, Leppert PC. Mechanical signaling and extracellular matrix in uterine fibroids. Semin Reprod Med. 2017;35(6):487\u201393.","journal-title":"Semin Reprod Med"},{"issue":"7","key":"2016_CR64","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1210\/en.2018-00151","volume":"159","author":"MFB Jamaluddin","year":"2018","unstructured":"Jamaluddin MFB, Nahar P, Tanwar PS. Proteomic characterization of the extracellular matrix of human uterine fibroids. Endocrinology. 2018;159(7):2656\u201369.","journal-title":"Endocrinology"},{"issue":"1","key":"2016_CR65","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1056\/NEJMoa1302736","volume":"369","author":"M Mehine","year":"2013","unstructured":"Mehine M, et al. Characterization of uterine leiomyomas by whole-genome sequencing. N Engl J Med. 2013;369(1):43\u201353.","journal-title":"N Engl J Med"},{"issue":"6053","key":"2016_CR66","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1126\/science.1208930","volume":"334","author":"N Makinen","year":"2011","unstructured":"Makinen N, et al. MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas. Science. 2011;334(6053):252\u20135.","journal-title":"Science"},{"issue":"12","key":"2016_CR67","doi-asserted-by":"publisher","first-page":"966","DOI":"10.18632\/oncotarget.370","volume":"2","author":"N Makinen","year":"2011","unstructured":"Makinen N, et al. MED12 exon 2 mutations are common in uterine leiomyomas from South African patients. Oncotarget. 2011;2(12):966\u20139.","journal-title":"Oncotarget"},{"issue":"9","key":"2016_CR68","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1002\/humu.22612","volume":"35","author":"K Kampjarvi","year":"2014","unstructured":"Kampjarvi K, et al. Mutations in exon 1 highlight the role of MED12 in uterine leiomyomas. Hum Mutat. 2014;35(9):1136\u201341.","journal-title":"Hum Mutat"},{"issue":"2","key":"2016_CR69","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s00438-014-0938-x","volume":"290","author":"SK Halder","year":"2015","unstructured":"Halder SK, et al. Novel MED12 gene somatic mutations in women from the Southern United States with symptomatic uterine fibroids. Mol Genet Genomics. 2015;290(2):505\u201311.","journal-title":"Mol Genet Genomics"},{"issue":"3","key":"2016_CR70","doi-asserted-by":"publisher","first-page":"e33251","DOI":"10.1371\/journal.pone.0033251","volume":"7","author":"MM McGuire","year":"2012","unstructured":"McGuire MM, et al. Whole exome sequencing in a random sample of North American women with leiomyomas identifies MED12 mutations in majority of uterine leiomyomas. PLoS One. 2012;7(3):e33251.","journal-title":"PLoS One"},{"issue":"11","key":"2016_CR71","doi-asserted-by":"publisher","first-page":"4283","DOI":"10.1210\/jc.2018-00863","volume":"103","author":"MJ Park","year":"2018","unstructured":"Park MJ, et al. Mediator kinase disruption in MED12-mutant uterine fibroids from Hispanic women of South Texas. J Clin Endocrinol Metab. 2018;103(11):4283\u201392.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2016_CR72","first-page":"592","volume":"158","author":"A Al-Hendy","year":"2017","unstructured":"Al-Hendy A, et al. Silencing Med12 gene reduces proliferation of human leiomyoma cells mediated via Wnt\/beta-catenin signaling pathway. Endocrinology. 2017;158(3):592\u2013603.","journal-title":"Endocrinology"},{"issue":"1","key":"2016_CR73","doi-asserted-by":"publisher","first-page":"4057","DOI":"10.1038\/s41467-023-39684-y","volume":"14","author":"K Buyukcelebi","year":"2023","unstructured":"Buyukcelebi K, et al. Engineered MED12 mutations drive leiomyoma-like transcriptional and metabolic programs by altering the 3D genome compartmentalization. Nat Commun. 2023;14(1):4057.","journal-title":"Nat Commun"},{"issue":"3","key":"2016_CR74","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.xfss.2022.04.002","volume":"3","author":"T Takao","year":"2022","unstructured":"Takao T, et al. A mediator complex subunit 12 gain-of-function mutation induces partial leiomyoma cell properties in human uterine smooth muscle cells. F&S Science. 2022;3(3):288\u201398.","journal-title":"F&S Science"},{"key":"2016_CR75","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24043742","author":"T-D Chuang","year":"2023","unstructured":"Chuang T-D, et al. Differential expression of MED12-associated coding RNA transcripts in uterine leiomyomas. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms24043742.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"2016_CR76","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.1091\/mbc.e08-01-0076","volume":"20","author":"KE Michael","year":"2009","unstructured":"Michael KE, et al. Focal adhesion kinase modulates cell adhesion strengthening via integrin activation. Mol Biol Cell. 2009;20(9):2508\u201319.","journal-title":"Mol Biol Cell"},{"issue":"9","key":"2016_CR77","doi-asserted-by":"publisher","first-page":"998","DOI":"10.3390\/bioengineering10090998","volume":"10","author":"BK Verma","year":"2023","unstructured":"Verma BK, et al. Substrate stiffness modulates TGF-beta activation and ECM-associated gene expression in fibroblasts. Bioengineering (Basel). 2023;10(9):998.","journal-title":"Bioengineering (Basel)"},{"key":"2016_CR78","doi-asserted-by":"publisher","first-page":"120331","DOI":"10.1016\/j.biomaterials.2020.120331","volume":"259","author":"S Vermeulen","year":"2020","unstructured":"Vermeulen S, et al. Mechanotransduction is a context-dependent activator of TGF-beta signaling in mesenchymal stem cells. Biomaterials. 2020;259:120331.","journal-title":"Biomaterials"},{"key":"2016_CR79","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.764727","volume":"9","author":"CH Stuelten","year":"2021","unstructured":"Stuelten CH, Zhang YE. Transforming growth factor-beta: an agent of change in the tumor microenvironment. Front Cell Dev Biol. 2021;9:764727.","journal-title":"Front Cell Dev Biol"},{"issue":"3","key":"2016_CR80","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s12079-014-0234-x","volume":"8","author":"C Fujisawa","year":"2014","unstructured":"Fujisawa C, Castellot JJ Jr. Matrix production and remodeling as therapeutic targets for uterine leiomyoma. J Cell Commun Signal. 2014;8(3):179\u201394.","journal-title":"J Cell Commun Signal"},{"issue":"5","key":"2016_CR81","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1055\/s-0033-1348896","volume":"31","author":"WH Catherino","year":"2013","unstructured":"Catherino WH, Eltoukhi HM, Al-Hendy A. Racial and ethnic differences in the pathogenesis and clinical manifestations of uterine leiomyoma. Semin Reprod Med. 2013;31(5):370\u20139.","journal-title":"Semin Reprod Med"},{"issue":"1","key":"2016_CR82","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1067\/mob.2003.99","volume":"188","author":"DD Baird","year":"2003","unstructured":"Baird DD, et al. High cumulative incidence of uterine leiomyoma in Black and White women: ultrasound evidence. Am J Obstet Gynecol. 2003;188(1):100\u20137.","journal-title":"Am J Obstet Gynecol"},{"issue":"6","key":"2016_CR83","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.ajog.2010.02.039","volume":"202","author":"VL Jacoby","year":"2010","unstructured":"Jacoby VL, et al. Racial and ethnic disparities in benign gynecologic conditions and associated surgeries. Am J Obstet Gynecol. 2010;202(6):514\u201321.","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"2016_CR84","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.ogc.2016.11.007","volume":"44","author":"SK Laughlin-Tommaso","year":"2017","unstructured":"Laughlin-Tommaso SK, Jacoby VL, Myers ER. Disparities in fibroid incidence, prognosis, and management. Obstet Gynecol Clin North Am. 2017;44(1):81\u201394.","journal-title":"Obstet Gynecol Clin North Am"},{"issue":"6","key":"2016_CR85","doi-asserted-by":"publisher","first-page":"591.e1","DOI":"10.1016\/j.ajog.2018.09.039","volume":"219","author":"O Yu","year":"2018","unstructured":"Yu O, et al. A US population-based study of uterine fibroid diagnosis incidence, trends, and prevalence: 2005 through 2014. Am J Obstet Gynecol. 2018;219(6):591.e1-591.e8.","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"2016_CR86","first-page":"225","volume":"62","author":"H Cook","year":"2010","unstructured":"Cook H, et al. The impact of uterine leiomyomas on reproductive outcomes. Minerva Ginecol. 2010;62(3):225\u201336.","journal-title":"Minerva Ginecol"},{"issue":"7","key":"2016_CR87","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/j.jmig.2020.11.008","volume":"28","author":"JS Ko","year":"2021","unstructured":"Ko JS, et al. Association of race\/ethnicity with surgical route and perioperative outcomes of hysterectomy for leiomyomas. J Minim Invasive Gynecol. 2021;28(7):1403\u201310.e2.","journal-title":"J Minim Invasive Gynecol"},{"issue":"2","key":"2016_CR88","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1097\/AOG.0000000000002738","volume":"132","author":"NC Stentz","year":"2018","unstructured":"Stentz NC, et al. Association of patient race with surgical practice and perioperative morbidity after myomectomy. Obstet Gynecol. 2018;132(2):291\u20137.","journal-title":"Obstet Gynecol"},{"issue":"1","key":"2016_CR89","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.whi.2018.08.005","volume":"29","author":"LS Callegari","year":"2019","unstructured":"Callegari LS, et al. Associations between race\/ethnicity, uterine fibroids, and minimally invasive hysterectomy in the VA healthcare system. Womens Health Issues. 2019;29(1):48\u201355.","journal-title":"Womens Health Issues"},{"issue":"12","key":"2016_CR90","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1097\/MLR.0000000000001200","volume":"57","author":"JG Katon","year":"2019","unstructured":"Katon JG, et al. Contributors to racial disparities in minimally invasive hysterectomy in the US department of veterans affairs. Med Care. 2019;57(12):930\u20136.","journal-title":"Med Care"},{"issue":"1","key":"2016_CR91","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1093\/humrep\/dei309","volume":"21","author":"JJ Wei","year":"2006","unstructured":"Wei JJ, et al. Ethnic differences in expression of the dysregulated proteins in uterine leiomyomata. Hum Reprod. 2006;21(1):57\u201367.","journal-title":"Hum Reprod"},{"key":"2016_CR92","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/1477-7827-5-34","volume":"5","author":"Q Pan","year":"2007","unstructured":"Pan Q, Luo X, Chegini N. Genomic and proteomic profiling I: leiomyomas in African Americans and Caucasians. Reprod Biol Endocrinol. 2007;5:34.","journal-title":"Reprod Biol Endocrinol"},{"issue":"4","key":"2016_CR93","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1530\/ERC-12-0007","volume":"19","author":"TD Chuang","year":"2012","unstructured":"Chuang TD, et al. miR-200c is aberrantly expressed in leiomyomas in an ethnic-dependent manner and targets ZEBs, VEGFA, TIMP2, and FBLN5. Endocr Relat Cancer. 2012;19(4):541\u201356.","journal-title":"Endocr Relat Cancer"},{"issue":"4","key":"2016_CR94","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1002\/gcc.20415","volume":"46","author":"T Wang","year":"2007","unstructured":"Wang T, et al. A micro-RNA signature associated with race, tumor size, and target gene activity in human uterine leiomyomas. Genes Chromosomes Cancer. 2007;46(4):336\u201347.","journal-title":"Genes Chromosomes Cancer"},{"key":"2016_CR95","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.160274","author":"EN Paul","year":"2022","unstructured":"Paul EN, et al. Transcriptome and DNA methylome analyses reveal underlying mechanisms for the racial disparity in uterine fibroids. JCI Insight. 2022. https:\/\/doi.org\/10.1172\/jci.insight.160274.","journal-title":"JCI Insight"},{"issue":"4","key":"2016_CR96","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.bpobgyn.2008.01.014","volume":"22","author":"EE Othman","year":"2008","unstructured":"Othman EE, Al-Hendy A. Molecular genetics and racial disparities of uterine leiomyomas. Best Pract Res Clin Obstet Gynaecol. 2008;22(4):589\u2013601.","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"issue":"2","key":"2016_CR97","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.jsgi.2005.10.007","volume":"13","author":"A Al-Hendy","year":"2006","unstructured":"Al-Hendy A, Salama SA. Catechol-O-methyltransferase polymorphism is associated with increased uterine leiomyoma risk in different ethnic groups. J Soc Gynecol Investig. 2006;13(2):136\u201344.","journal-title":"J Soc Gynecol Investig"},{"issue":"3","key":"2016_CR98","doi-asserted-by":"publisher","first-page":"324.e1","DOI":"10.1016\/j.ajog.2024.05.048","volume":"231","author":"MV Bariani","year":"2024","unstructured":"Bariani MV, et al. Altered extracellular matrix-related pathways accelerate the transition from normal to prefibroid myometrium in Black women. Am J Obstet Gynecol. 2024;231(3):324.e1-324.e12.","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"2016_CR99","doi-asserted-by":"publisher","first-page":"321.e1","DOI":"10.1016\/j.ajog.2024.04.051","volume":"231","author":"NW Bateman","year":"2024","unstructured":"Bateman NW, et al. Multiomic analysis of uterine leiomyomas in self-described Black and White women: molecular insights into health disparities. Am J Obstet Gynecol. 2024;231(3):321.e1-321.e11.","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"2016_CR100","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1097\/AOG.0000000000002462","volume":"131","author":"JA Simon","year":"2018","unstructured":"Simon JA, et al. Ulipristal acetate for treatment of symptomatic uterine leiomyomas: a randomized controlled trial. Obstet Gynecol. 2018;131(3):431\u20139.","journal-title":"Obstet Gynecol"},{"issue":"5","key":"2016_CR101","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1056\/NEJMoa1103182","volume":"366","author":"J Donnez","year":"2012","unstructured":"Donnez J, et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med. 2012;366(5):409\u201320.","journal-title":"N Engl J Med"},{"issue":"3","key":"2016_CR102","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.xfre.2024.06.002","volume":"5","author":"JA Simon","year":"2024","unstructured":"Simon JA, et al. Impact of demographic and clinical factors on elagolix plus add-back therapy effects on patient-reported nonbleeding symptoms in women with heavy menstrual bleeding and uterine fibroids: a post hoc analysis of data from two clinical trials. F&S Reports. 2024;5(3):285\u201395.","journal-title":"F&S Reports"},{"issue":"4","key":"2016_CR103","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1034\/j.1600-0412.2003.00049.x","volume":"82","author":"N Bozzini","year":"2003","unstructured":"Bozzini N, et al. Effects of treatment with gonadotropin releasing hormone agonist on the uterine leiomyomata structure. Acta Obstet Gynecol Scand. 2003;82(4):330\u20134.","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"12","key":"2016_CR104","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1177\/1933719114553449","volume":"21","author":"LN Brunengraber","year":"2014","unstructured":"Brunengraber LN, Jayes FL, Leppert PC. Injectable Clostridium histolyticum collagenase as a potential treatment for uterine fibroids. Reprod Sci. 2014;21(12):1452\u20139.","journal-title":"Reprod Sci"},{"issue":"2","key":"2016_CR105","doi-asserted-by":"publisher","first-page":"207.e1","DOI":"10.1016\/j.ajog.2022.09.024","volume":"228","author":"K Nagai","year":"2023","unstructured":"Nagai K, et al. MED12 mutations in uterine leiomyomas: prediction of volume reduction by gonadotropin-releasing hormone agonists. Am J Obstet Gynecol. 2023;228(2):207.e1-207.e9.","journal-title":"Am J Obstet Gynecol"},{"key":"2016_CR106","doi-asserted-by":"publisher","unstructured":"Mason B, Califano J. Matrix stiffness: a regulator of cellular behavior and tissue formation. In: Bhatia A, editor. Engineering biomaterials for regenerative medicine. New York: Springer; 2012. p. 19\u201337. https:\/\/doi.org\/10.1007\/978-1-4614-1080-5_2.","DOI":"10.1007\/978-1-4614-1080-5_2"},{"issue":"9","key":"2016_CR107","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1177\/1933719114545240","volume":"21","author":"M Malik","year":"2014","unstructured":"Malik M, et al. Leiomyoma cells in 3-dimensional cultures demonstrate an attenuated response to fasudil, a rho-kinase inhibitor, when compared to 2-dimensional cultures. Reprod Sci. 2014;21(9):1126\u201338.","journal-title":"Reprod Sci"}],"container-title":["Reproductive Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43032-025-02016-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43032-025-02016-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43032-025-02016-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T15:11:16Z","timestamp":1781622676000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43032-025-02016-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,8]]},"references-count":107,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["2016"],"URL":"https:\/\/doi.org\/10.1007\/s43032-025-02016-0","relation":{},"ISSN":["1933-7191","1933-7205"],"issn-type":[{"value":"1933-7191","type":"print"},{"value":"1933-7205","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,8]]},"assertion":[{"value":"5 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"IRB-approved protocol from the University of Chicago (IRB #20\u20131414).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Written informed patient consent was used.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"This original work hasn\u2019t been published elsewhere.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}}]}}